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terms of the Creativ
share the work provObjective: To evaluate changes in weight and BMI in adults with HIV-1 at 1 and 2 years
after starting an antiretroviral regimen that included doravirine, ritonavir-boosted
darunavir, or efavirenz.
Design: Post-hoc analysis of pooled data from three randomized controlled trials.
Methods: We evaluated weight change from baseline, weight gain at least 10%, and
increase in BMI after 48 and 96 weeks of treatment with doravirine, ritonavir-boosted
darunavir, or efavirenz-based regimens. Risk factors for weight gain and metabolic
outcomes associated with weight gain were also examined.
Results: Mean (and median) weight changes were similar for doravirine [1.7 (1.0) kg]
and ritonavir-boosted darunavir [1.4 (0.6) kg] and were lower for efavirenz [0.6
(0.0) kg] at week 48 but were similar across all treatment groups at week 96 [2.4
(1.5), 1.8 (0.7), and 1.6 (1.0) kg, respectively]. No significant differences between
treatment groups were found in the proportion of participants with at least 10% weight
gain or the proportion with BMI class increase at either time point. Low CD4þ T-cell
count and high HIV-1 RNA at baseline were associated with at least 10% weight gain
and BMI class increase at both timepoints, but treatment group, age, sex, and race
were not.
Conclusion: Weight gains over 96 weeks were low in all treatment groups and were
similar to the average yearly change in adults without HIV-1. Significant weight gain
and BMI class increase were similar across the treatment groups and were predicted by
low baseline CD4þ T-cell count and high baseline HIV-1 RNA.
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Adults tend to gain weight progressively through middle
age, with an average weight gain estimated at 0.5–1 kg/
year [1]. Over time, this modest accumulation of weight
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92 AIDS 2021, Vol 35 No 1other health problems including cardiovascular disease,
diabetes, certain cancers, and nonalcoholic fatty liver
disease [4,5].
For people living with HIV (PLWH), weight gain
after starting antiretroviral therapy (ART) is often
considered a return to health. Weight gain during the
first year after ART initiation has been associated with
lower mortality in underweight and normal-weight
patients, but not in overweight or obese patients [6],
whereas other studies have linked weight gain during
HIV treatment to increased risk for diabetes, cardiovas-
cular disease, hepatic steatosis, and liver fibrosis [7–10].
Since the introduction of more effective and better
tolerated ART, the prevalence of being overweight or
obese has increased among PLWH [11–16]. Women
with HIVare at higher risk than men for weight gain and
obesity following ART initiation [17,18]. Other risk
factors for weight gain in PLWH include lower BMI,
higher CD4þ T-cell count, and lower HIV RNA at
diagnosis [12–15].
Data from observational studies and randomized trials
suggest that regimens containing an integrase strand-
transfer inhibitor (InSTI) are associated with greater
weight gain than other regimens [19]. In a pooled analysis
of eight randomized controlled trials [20], mean weight
gain after 96 weeks was higher with InSTI-based
regimens than with protease inhibitor or nonnucleoside
reverse transcriptase inhibitor (NNRTI)-based regimens,
and with tenofovir alafenamide/emtricitabine (FTC)
compared with other NRTI pairs, in a population that
was predominantly male (88%) and white (62%). Similar
patterns have been observed in women [21] and in black
PLWH [22,23]. The mechanism for this association is
currently unknown; proposed explanations include
improved gastrointestinal tolerability, faster virologic
control, interference with the melanocortin 4 receptor
[24], and promotion of adipocyte hypertrophy, fibrosis,
and insulin resistance [25].
Doravirine (DOR) is a next-generation NNRTI for the
treatment of HIV-1, available as a single entity and as a
fixed combination with lamivudine and tenofovir
disoproxil fumarate (DOR/3TC/TDF). Clinical trials
in treatment-naı̈ve adults have shown that DOR-based
regimens have noninferior efficacy and a superior lipid
profile compared with ritonavir-boosted darunavir
(DRVþr) [26] and efavirenz (EFV)-based regimens
[27], as well as significantly fewer neuropsychiatric events
than EFV-based regimens [27,28]. In adults with HIV-1
who switched from a stable ART regimen, DOR/3TC/
TDF maintained virologic suppression for 48 weeks and
demonstrated a favorable safety and tolerability profile,
which included improved lipid profiles compared with
continuation of a boosted protease inhibitor regimen
[29]. Using data from three randomized controlled trials
of DOR, we conducted a post-hoc analysis of changes inweight and BMI in treatment-naive adults with HIV-1
who received combination therapy with two NRTIs and
either DOR, DRVþr, or EFV for 96 weeks.Methods
Data were pooled from three double-blind, randomized
controlled trials of DOR in treatment-naive adults with
HIV-1: MK-1439A Protocol 007 (P007; NCT01632345),
DRIVE-FORWARD (NCT02275780), and DRIVE-
AHEAD (NCT02403674). P007 [28] was a phase 2b dose-
ranging study of DOR 25–200 mg and EFV 600 mg, each
given in combination with FTC/TDF. DRIVE-FOR-
WARD [26] is a phase 3 noninferiority trial comparing
DOR and DRVþr, each given in combination with 2
NRTIs, and DRIVE-AHEAD [27] is a phase 3
noninferiority trial comparing DOR/3TC/TDF and
EFV/FTC/TDF. The 96-week blinded phase of both
phase 3 trials has completed, and the open-label extension
phases are ongoing. All three trials were conducted in
compliance with Good Clinical Practice requirements and
applicable statutes and regulations regarding ethical
committee review, informed consent, and the protection
of humans participating in biomedical research.
Double-blind data through week 96 of each trial were
combined by treatment group. The combined DOR
group included participants who received DOR 100 mg
with two NRTIs in P007 or DRIVE-FORWARD and
those who received DOR/3TC/TDF in DRIVE-
AHEAD. The DRVþr group included participants
who received DRVþr with two NRTIs in DRIVE-
FORWARD, and the combined EFV group included
participants who received EFV 600 mg with two NRTIs
in P007 or EFV/FTC/TDF in DRIVE-AHEAD. All
participants who received at least one dose of study
medication were included in the analyses.
Statistical analysis
The endpoints of interest were the change in weight
from baseline, the proportion of participants with at least
10% weight gain, and the proportion of participants with
an increase in BMI class. The change in weight from
baseline was calculated as the mean change with 95%
confidence interval (CI), and as the median change
with interquartile range, at weeks 48 and 96 for each
treatment group.
For the proportion of participants with at least 10%
weight gain, the treatment groups were compared using
generalized linear models with binomial distribution and
identity link. Explanatory variables included in the model
were treatment group, region, sex, indicator for race
(black/nonblack), interaction terms of treatment by sex
and by race indicator, and baseline values of age, weight,
BMI, log10 CD4
þ T-cell count, and log10 HIV-1 RNA.
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treatment differences reflected the study population,
observed marginal proportions for region, sex, and black/
nonblack were used in the model.
BMI categories were defined as follows: underweight,
BMI less than 18.5; normal weight, BMI at least 18.5 to
less than 25; overweight, BMI at least 25 to less than 30;
and obese, BMI at least 30. An increase in BMI class was
defined as a change from underweight or normal at
baseline to overweight or obese at week 48 or 96, or a
change from overweight at baseline to obese at week 48 or
96. A generalized linear model with binomial distribution
and identity link was used to estimate the proportions in
each treatment group with BMI class increase and the
differences between DOR and the comparators, adjusting
for region, sex, race group, and baseline values of age,
BMI, log10 CD4
þ T-cell counts, and log10 HIV-1 RNA.
Three race groups with small numbers of participants
(American Indian or Alaska Native, Multiracial, and
Native Hawaiian or Pacific Islander) were combined for
model feasibility.
We also examined the relationship between weight gain
status and the following metabolic endpoints: change
from baseline in total cholesterol (TC), LDL cholesterol
(LDL-C), HDL cholesterol, and triglycerides; develop-
ment of hypertension or diabetes; and new use of
antihypertensive, antidiabetic, or lipid-lowering medica-
tion. Information regarding new diagnosis of hyperten-
sion or diabetes was not specifically collected in the DOR
trials; for this analysis, these ‘new diagnoses’ were
identified by reviewing the adverse events spontaneously
reported by the participants, which may or may not
reflect a true medical diagnosis. Antihypertensive
medications included angiotensin-converting enzyme
inhibitors, angiotensin II antagonists, beta-blockers,
calcium channel blockers, and diuretics; these medica-
tions are sometimes used to treat conditions other
than hypertension.
Participants were classified into two weight-gain groups
according to their percentage weight gain at week 96; the
high-gain group included participants with at least 10%
weight gain, and the low-gain group included those with
less than 10% weight gain. Changes from baseline in lipid
endpoints, the proportions of participants with new
hypertension or diabetes, and the proportions with new
medication use were summarized by weight-gain group
within each treatment group. Realizing that the observed
differences between the two weight-gain groups could be
confounded by differences in their baseline character-
istics, we further analyzed the data adjusting for
baseline variables.
The change from baseline in lipid endpoints was analyzed
using a repeated measure mixed model, and the
proportion of participants with new medication usewas analyzed using generalized linear models with
binomial distribution and identity link. The explanatory
variables included treatment group, weight-gain group,
their interaction, and other significant variables selected
based on their statistical significance in models with these
variables individually or in combination, depending on
the endpoint being analyzed. The potential explanatory
variables to enter the models were age, sex, black or
African-American race, baseline weight, baseline CD4þ
cell counts, and log of baseline viral load.Results
A total of 1710 participants were included in the pooled
analyses: 855 received DOR, 383 received DRVþr, and
472 received EFV. The study population was 85% male,
63% white, and 20% black or African-American. At
baseline, the majority of participants (55.8%) were in the
normal weight category (BMI 18.5–<25), 3.9% were
underweight (BMI< 18.5), 29.1% were overweight
(BMI 25–<30), and 11.2% were obese (BMI 30)
(refer to Table, Supplemental Digital Content 1, http://
links.lww.com/QAD/B868, for additional participant
characteristics).
Change in body weight
At week 48, mean weight gain was similar in the DOR
group [1.7 kg, 95% CI (1.4, 2.1)] and the DRVþr group
[1.4 kg (0.6, 2.1)] and slightly lower in the EFV group
[0.6 kg (0.1, 1.2)]. Greater weight gains were observed
in all treatment groups at week 96, and the mean change
was similar across the groups [2.4 (1.9, 2.8), 1.8 (0.8, 2.7),
and 1.6 (0.9, 2.3) kg, respectively]. Median weight gains
were consistently lower than the mean values at week 48:
DOR 1.0 kg (interquartile range: 1.2, 3.9), DRVþr
0.6 kg (1.9, 3.4), and EFV 0.0 kg (2.6, 2.8); and at
week 96: DOR 1.5 kg (1.0, 4.9), DRVþr 0.7 kg (1.9,
5.1), and EFV 1.0 kg (2.2, 4.6).
The majority of participants in each treatment group
experienced less than 5% weight gain (Fig. 1). The
proportion of participants with at least 5% weight gain at
week 48 was similar in the DOR and DRVþr groups
(26.5 and 23.1%, respectively) and was lower in the EFV
group (20.6%); by week 96 the proportion with at least
5% weight gain was similar across all treatment groups
(DOR 31.8%, DRVþr 32.8%, and EFV 32.0%). Weight
gain of 10% or more was observed in 8–10% of
participants at week 48 and in 14–16% of participants at
week 96 (Fig. 1) and was not significantly different
between the treatment groups at either time point after
adjusting for baseline factors (Fig. 2).
Change in BMI
The majority of participants in each treatment group
remained in their baseline BMI class at weeks 48















































≥5% to <10% ≥10%<5%Weight Change Category:
Combined DOR                 DRV+r Combined EFV Combined DOR                 DRV+r Combined EFV
Fig. 1. Distribution of participants by percentage change in weight (<5, >–5 to <10, >–10%). DOR, doravirine; DRVþr, ritonavir-
boosted darunavir; EFV, efavirenz.and 96 (Table 1). Among participants who were not
obese at baseline, the proportion who were overweight
increased over time in all treatment groups (Fig. 3), and a
small proportion became obese by week 96 (DOR 7%,
DRVþr 6%, and EFV 5%). The proportion of
participants whose BMI class increased to overweight
or obese was not significantly different between the
DOR group and either of the comparator groups at



























Fig. 2. Proportion of participants with at least 10% weight gain. Es
group differences (doravirine minus comparator) are from the ge
boosted darunavir; EFV, efavirenz.Risk factors for weight gain and BMI class
increase
Low baseline CD4þ T-cell count and high baseline HIV-
1 RNA were significant factors for at least 10% weight
gain at weeks 48 and 96 (all P< 0.001) and for BMI class
increase at week 48 (P¼ 0.002 and 0.016, respectively)
and week 96 (P¼ 0.002 and 0.010, respectively). We did
not find significant associations between treatment group,





Variable Week 48    p-value







BL Weight 0.682 0.149
BL BMI 0.068 0.138
BL CD4+ cell count <0.001 <0.001
BL HIV-1 RNA <0.001 <0.001
timated proportions and 95% confidence interval for treatment
neralized linear model. DOR, doravirine; DRVþr, ritonavir-
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Table 1. Shift in BMI class at weeks 48 and 96 by baseline BMI category and treatment group.
Study week Baseline BMI group Study week BMI group Combined DOR, n (%) Main DRVþr, n (%) Combined EFV, n (%)
Week 48 Underweight Total 26 13 20
Underweight 16 (61.5) 8 (61.5) 14 (70.0)
Normal 9 (34.6) 4 (30.8) 5 (25.0)
Overweight 0 1 (7.7) 1 (5.0)
Obese 1 (3.8) 0 0
Normal Total 412 168 231
Underweight 13 (3.2) 1 (0.6) 8 (3.5)
Normal 348 (84.5) 141 (83.9) 201 (87.0)
Overweight 48 (11.7) 24 (14.3) 21 (9.1)
Obese 3 (0.7) 2 (1.2) 1 (0.4)
Overweight Total 229 102 111
Underweight 0 0 1 (0.9)
Normal 14 (6.1) 15 (14.7) 21 (18.9)
Overweight 183 (79.9) 79 (77.5) 79 (71.2)
Obese 32 (14.0) 8 (7.8) 10 (9.0)
Obese Total 84 33 40
Overweight 9 (10.7) 5 (15.2) 6 (15.0)
Obese 75 (89.3) 28 (84.8) 34 (85.0)
Week 96 Underweight Total 24 11 19
Underweight 13 (54.2) 7 (63.6) 8 (42.1)
Normal 10 (41.7) 4 (36.4) 10 (52.6)
Obese 1 (4.2) 0 1 (5.3)
Normal Total 377 140 211
Underweight 7 (1.9) 4 (2.9) 3 (1.4)
Normal 301 (79.8) 108 (77.1) 172 (81.5)
Overweight 65 (17.2) 26 (18.6) 35 (16.6)
Obese 4 (1.1) 2 (1.4) 1 (0.5)
Overweight Total 200 91 93
Normal 21 (10.5) 10 (11.0) 15 (16.1)
Overweight 140 (70.0) 68 (74.7) 65 (69.9)
Obese 39 (19.5) 13 (14.3) 13 (14.0)
Obese Total 76 26 39
Normal 0 1 (3.8) 0
Overweight 8 (10.5) 9 (34.6) 3 (7.7)
Obese 68 (89.5) 16 (61.5) 36 (92.3)
BMI groups: underweight is less than 18.5, normal is at least 18.5 to less than 25, overweight is at least 25 to less than 30, obese is at least 30. Values
in bold are the proportion of participants whose BMI on treatment remained in the baseline BMI category. DOR, doravirine; DRVþr, ritonavir-




























































Baseline Week 48 Week 96
Combined EFV
Fig. 3. Overall change in BMI class through week 96 (obese at baseline excluded). DOR, doravirine; DRVþr, ritonavir-boosted
darunavir; EFV, efavirenz.


















Week 48 Week 96
















Group 0.172 0.773 




BL BMI 0.245 0.088
BL CD4+ cell count 0.002 0.002
BL HIV-1 RNA 0.016 0.010 
Fig. 4. Proportion of participants with BMI class increase to overweight or obese. Estimated proportions and 95% confidence
interval for treatment group differences (doravirine minus comparator) are from the generalized linear model. DOR, doravirine;
DRVþr, ritonavir-boosted darunavir; EFV, efavirenz.baseline characteristics (weight, BMI, region) and at least
10% weight gain or BMI class increase in the multivariate
model. However, mean weight gain was numerically
higher in women than in men, and in black participants
compared with nonblack participants, in all treatment
groups at both time points (refer to Table, Supplemental
Digital Content 2, http://links.lww.com/QAD/B869).
Similarly, the proportion of participants with weight gain
at least 10% was numerically higher in women than in
men in all treatment groups at both time points, and in
black participants compared with nonblack participants
except in the DRVþr group at week 96 (refer to Table,
Supplemental Digital Content 3, http://links.lww.com/
QAD/B870).
Metabolic changes associated with weight gain
In all treatment groups, participants with high weight gain
had larger mean increases in TC and LDL-C compared
with those with low weight gain (refer to Figure,
Supplemental Digital Content 4, http://links.lww.com/
QAD/B871), although the 95% CIs overlapped in most
cases. The mean changes in triglycerides followed a
similar pattern in the DOR and EFV groups. New use of
lipid-lowering therapy was generally low and similar
between participants with high weight gain and those
with low weight gain (refer to Table, Supplemental
Digital Content 5, http://links.lww.com/QAD/B872).
In all treatment groups, new diagnosis of hypertension
and new use of antihypertensive medication were more
common in participants with high weight gain than in
those with low weight gain, even after adjusting for
statistically significant variables of age, black race, and
baseline weight, although the 95% CIs for the differences
were wide and included zero (refer to Table,Supplemental Digital Content 6, http://links.lww.-
com/QAD/B873). New diagnosis of diabetes and new
use of diabetes medication were low and similar between
participants with high weight gain and those with low
weight gain in all treatment groups (refer to Table,
Supplemental Digital Content 7, http://links.lww.com/
QAD/B874).Discussion
The current post-hoc analysis of three randomized
controlled trials is the first examination of weight changes
during treatment with DOR, a next-generation NNRTI
first approved in 2018 for the treatment of HIV-1. In this
analysis, ART-naive participants who received DOR,
DRVþr, or EFV-based regimens experienced weight
gains that were similar to the average yearly change of
0.5–1.0 kg in adults without HIV-1 [1]: mean weight
gain after 2 years of treatment was 2.4 kg in the DOR
group, 1.8 kg in the DRVþr group, and 1.6 kg in the EFV
group. Significant weight gain (10%) occurred in 15%
of participants overall by week 96 and was not
significantly different between the DOR, DRVþr, and
EFV groups (16, 17, and 13%, respectively). The
proportion of participants whose BMI class increased
also was similar across the treatment groups (16, 15, and
14%, respectively).
Our results are consistent with a recent meta-analysis of 8
clinical trials that found weight gains of similar magnitude
after 96 weeks of treatment with an NNRTI-based
regimen [1.9 kg (95% CI 1.6–2.3)] or a boosted
Weight and BMI changes with doravirine Orkin et al. 97atazanavir regimen [1.7 kg (95% CI 1.0–2.4)] [20]. In a
retrospective cohort study of 1152 ART-naive PLWH,
weight gain after 18 months of treatment also was
comparable for regimens containing an NNRTI (EFVor
rilpivirine) [2.6 kg (95% CI 1.5–3.6)] and those contain-
ing a boosted protease inhibitor (DRV or atazanavir)
[4.1 kg (95% CI 3.2–5.0)] [30]. In contrast, other studies
have found higher weight gain with protease inhibitor-
based regimens than with NNRTI-based regimens: a post
hoc exploratory analysis of ACTG study A5224 s found
significantly greater weight gain with boosted atazanavir
than with EFV (mean difference 3.4 kg, P¼ 0.02) after 96
weeks of treatment [31], and the Swiss HIV Cohort Study
found a larger BMI increase with atazanavir/ritonavir
compared with EFV (P¼ 0.03) after 4 years of treatment
[12]. In a recent observational study of 22,972 ART-naive
adults who initiated treatment during 2007–2016, those
starting an NNRTI-based regimen had lower 2-year
mean weight gain (3.1 kg) compared with InSTI and
protease inhibitor-based regimens (each 4.9 kg) [32].
Since the DOR trials did not include an InSTI-based
regimen as a comparator, it is not clear how the weight
changes we observed with DOR compare with those
recently reported for InSTI-based regimens [20–
23,30,32].
We found that indicators of more severe disease (low
CD4þ T-cell count and high HIV-1 RNA at baseline)
were significant factors for at least 10% weight gain and
BMI class increase, consistent with results from other
randomized controlled trials [20] as well as observational
cohort studies [6,13,15,16], and with the return-to-
health effect of HIV treatment. However, we did not find
an association between baseline BMI and at least 10%
weight gain or BMI class increase.
In our subgroup analyses, mean weight gain tended to be
higher in women and in black participants, consistent
with other reports [17,20–23]. However, sex and race
were not consistently identified as significant factors for at
least 10% weight gain or BMI class increase in the
multivariate analyses. The low proportion of women
(15%) and black participants (20%) in this study may have
limited the ability to detect significant associations for
these variables.
Being overweight or obese may increase the risk of
metabolic and cardiovascular disorders (CVD) in PLWH
[4,5], although the mechanism for these observations has
not been elucidated. In our study population, participants
with at least 10% weight gain appeared to be at higher risk
for elevated cholesterol and LDL-C, as well as the
development of hypertension and start of antihyperten-
sive medication. Dyslipidemia and hypertension are
among the traditional risk factors that contribute to
increased risk of CVD in PLWH [33,34]. In addition,
HIV infection is an independent risk factor for
myocardial infarction and other CVD [35–37]; thus,maintaining normal weight may provide an important
opportunity to avoid additional CVD risk in this
population.
Our results should be interpreted with caution because
these analyses were not prespecified in the original study
plans. In addition, these analyses were not designed to
evaluate potential mechanisms for weight gain in PLWH.
Measurements of waist circumference and body fat
distribution were not collected in the DOR trials, so we
cannot determine whether the weight changes we
observed were generalized or localized. Future clinical
trials should include a more standardized approach to
weight gain and related variables such as waist
circumference, blood pressure, lipids, glucose, insulin,
and hemoglobin A1C. In addition, longer follow-up is
needed to understand the trajectory of weight and body
composition changes during long-term ART and the
impact on diabetes, cardiovascular disease, and nonalco-
holic fatty liver disease in PLWH.
Conclusion
The current post-hoc analyses show that weight gain in
treatment-naı̈ve adults with HIV-1 was low and similar
for DOR, DRVþr, and EFV-based regimens through 96
weeks of treatment, and that at least 10% weight gain was
associated with low CD4þ T-cell count and high HIV-1
RNA at baseline and with an increased risk of
hypertension and elevated plasma lipid levels at week
96. For patients who experience clinically meaningful
weight gain on ART, studies evaluating switch strategies
are needed to assist with HIV treatment selection. A post-
hoc analysis of weight change after switching from a stable
ART regimen to DOR/3TC/TDF in the DRIVE-
SHIFT trial is currently ongoing.Acknowledgements
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